Becker's Healthcare November 14, 2024
Alexandra Murphy

The FDA continues to face significant staffing shortages in its drug inspection workforce, according to a new report from the Government Accountability Office.

Despite some progress in resuming in-person inspections after COVID-19 disruptions, the report showed that the FDA is struggling to keep pace with the growing demand for oversight, particularly in foreign drug manufacturing.

The GAO’s findings highlight that while the FDA conducted 621 foreign and 444 domestic inspections in fiscal 2023, the total number of inspections was still 36% lower than pre-pandemic levels in 2019. The agency attributes the shortfall to reduced investigator capacity, exacerbated by...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, GAO, Govt Agencies, Survey / Study, Trends
Related Articles:
FDA updates definition of 'healthy'
FDA Clears Withings’ New Blood Pressure Monitor That Allows Providers to Communicate Directly with Patients
4 takeaways from the FDA’s first digital health advisory committee
FDA commissioner, a veteran cardiologist, highlights ongoing issues with US healthcare system
FDA commissioner urges health systems to strengthen AI quality oversight

Share This Article